Daines CL, Tullis E, Costa S, Linnemann RW, et al. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J 2023;62:2202029.
PMID: 37945033